Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAM360 AmnioGraft is a hydrated, cryopreserved amniotic membrane allograft developed by BioTissue for the treatment of ocular surface diseases. Utilizing proprietary SteriTrek and CryoTek preservation technologies, the product is shelf-stable at room temperature and retains the bioactive HC-HA/PTX3 complex responsible for its therapeutic properties. It exerts anti-inflammatory, anti-scarring, and anti-angiogenic effects to support tissue repair and ocular surface regeneration. The membrane is ringless and designed to adhere to the ocular surface under a bandage contact lens, making it suitable for treating conditions such as mild to moderate dry eye disease, superficial punctate keratitis, and neurotrophic keratitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CAM360 AmnioGraft.